AU2003233780A1 - Novel glucagon antagonists/inverse agonists - Google Patents

Novel glucagon antagonists/inverse agonists

Info

Publication number
AU2003233780A1
AU2003233780A1 AU2003233780A AU2003233780A AU2003233780A1 AU 2003233780 A1 AU2003233780 A1 AU 2003233780A1 AU 2003233780 A AU2003233780 A AU 2003233780A AU 2003233780 A AU2003233780 A AU 2003233780A AU 2003233780 A1 AU2003233780 A1 AU 2003233780A1
Authority
AU
Australia
Prior art keywords
inverse agonists
glucagon antagonists
novel glucagon
novel
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003233780A
Inventor
Carsten Behrens
Paw Bloch
Inge Thoger Christensen
Anker Steen Jorgensen
Janos Kodra Kodra
Jesper Lau
Peter Madsen
Poul Enrico Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003233780A1 publication Critical patent/AU2003233780A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2003233780A 2002-06-27 2003-05-27 Novel glucagon antagonists/inverse agonists Abandoned AU2003233780A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200201006 2002-06-27
DKPA200201006 2002-06-27
DKPA200201927 2002-12-17
DKPA200201927 2002-12-17
PCT/DK2003/000350 WO2004002480A1 (en) 2002-06-27 2003-05-27 Novel glucagon antagonists/inverse agonists

Publications (1)

Publication Number Publication Date
AU2003233780A1 true AU2003233780A1 (en) 2004-01-19

Family

ID=30001779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003233780A Abandoned AU2003233780A1 (en) 2002-06-27 2003-05-27 Novel glucagon antagonists/inverse agonists

Country Status (4)

Country Link
EP (1) EP1519723A1 (en)
JP (1) JP2006500325A (en)
AU (1) AU2003233780A1 (en)
WO (1) WO2004002480A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
BRPI0410348A (en) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compounds and uses thereof in amyloid-beta modulation
EP1758859B1 (en) * 2004-05-28 2013-07-17 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
DK1758853T3 (en) * 2004-06-14 2010-04-06 Lilly Co Eli Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
CA2574147A1 (en) * 2004-07-22 2006-02-09 Linda Brockunier Substituted pyrazoles, compositions containing such compounds and methods of use
WO2006074262A1 (en) * 2005-01-05 2006-07-13 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
PL1856090T3 (en) * 2005-02-11 2010-02-26 Lilly Co Eli Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP1910303A2 (en) 2005-07-26 2008-04-16 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AU2006306542B2 (en) * 2005-10-21 2012-04-19 Merck Sharp & Dohme Corp. Potassium channel inhibitors
JP5198280B2 (en) 2005-11-17 2013-05-15 イーライ リリー アンド カンパニー Glucagon receptor antagonists and their preparation and therapeutic use
EP1951661B1 (en) 2005-11-17 2012-08-08 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0618484A2 (en) 2005-11-18 2011-08-30 Lilly Co Eli compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods to inhibit the glucagon receptor in a mammal, to selectively reduce the glycemic level in a mammal and to treat type 2 diabetes, and, use of a compound or a salt thereof
BRPI0618140A2 (en) * 2005-11-22 2011-08-16 Lilly Co Eli pharmaceutically acceptable compound or salt thereof, pharmaceutical composition, and use of a compound or salt thereof
DK1957484T3 (en) 2005-11-23 2010-05-10 Lilly Co Eli Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
AU2007229850A1 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2009537525A (en) 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP5322951B2 (en) 2007-02-09 2013-10-23 リガンド・ファーマシューティカルズ・インコーポレイテッド Novel antagonist of glucagon receptor
WO2009057784A1 (en) * 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA2717138A1 (en) * 2008-03-05 2009-09-11 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds and bicyclic heteroaryl having glucagon antagonistic action useful for treating diabetes
EP2291358B1 (en) 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
EP2300437B1 (en) 2008-06-05 2013-11-20 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
KR101599089B1 (en) 2008-08-13 2016-03-02 메타베이시스 테라퓨틱스, 인크. Glucagon antagonists
AU2009326108A1 (en) * 2008-12-08 2010-06-17 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
CA2759476C (en) 2009-04-30 2018-10-09 Julie Nicole Hamblin Novel compounds
WO2011027849A1 (en) * 2009-09-04 2011-03-10 武田薬品工業株式会社 Heterocyclic compound
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US20130143927A1 (en) * 2011-06-10 2013-06-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8927577B2 (en) * 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
JP2017519000A (en) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド Glucagon antagonist
TW202003453A (en) 2018-02-13 2020-01-16 美商利根德製藥公司 Glucagon receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301501A2 (en) * 2000-06-23 2003-08-28 Novo Nordisk A/S Glucagon antagonists/inverse agonists, pharmaceutical compositions containing them and their use for preparation of pharmaceutical compositions
AU2002223501A1 (en) * 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists

Also Published As

Publication number Publication date
WO2004002480A1 (en) 2004-01-08
EP1519723A1 (en) 2005-04-06
JP2006500325A (en) 2006-01-05

Similar Documents

Publication Publication Date Title
AU2003233780A1 (en) Novel glucagon antagonists/inverse agonists
AU2003236205A1 (en) Glucagon antagonists/inverse agonists
AU2002365622A1 (en) Novel glucagon antagonists
IL163928A0 (en) Pyridinoylpiperidines as 5-htf agonists
AU2003290700A1 (en) Farnesoid x receptor agonists
AU2002347022A1 (en) Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2003224111A1 (en) Substituted pyrazolo-pyrimidine-4-ones
IL165841A0 (en) Mchir antagonists
AU2002341834A1 (en) Antagonists
AU2001255798A1 (en) Glucagon antagonists
AU2002223501A1 (en) Glucagon antagonists/inverse agonists
AU2003243637A1 (en) Cannabinoid receptor agonists
WO2003072535A8 (en) Substituted hydroxyethylamines
AU2003238043A1 (en) Substituted imidazotriazines
IL173521A0 (en) Substituted 2 - carbonylamino - 6 piperidinaminopyidines and substituted 1 - carbonylamino - 3 - piperidinaminobenzenes as 5 - th1f agonists
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2002951705A0 (en) Reflectometry
AU2002223500A1 (en) Glucagon antagonists/inverse agonists
GB0211257D0 (en) Novel heterocycles
AU2003291959A1 (en) Novel glucagon antagonists
AU2003303543A1 (en) Agonist antibody against heteroreceptor
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2003294900A1 (en) Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003212366A1 (en) Substituted 4-aminocyclohexanols

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase